









Markets
/
Stocks
/
nasdaq-xfor
/

X4 Pharmaceuticals Inc

XFOR

3.550USD

-0.420-10.58%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

28.26MMarket Cap

LossP/E TTM



X4 Pharmaceuticals Inc

3.550

-0.420-10.58%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of X4 Pharmaceuticals Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

X4 Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

108 / 159

Overall Ranking

276 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

8.400

Target Price

+111.59%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

X4 Pharmaceuticals Inc Highlights

StrengthsRisks

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.56M.

Overvalued

The company’s latest PE is -0.24, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 11.94M shares, increasing 37.83% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 17.37K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 13.21.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 6.95, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.97M, representing a year-over-year increase of 250.44%, while its net profit experienced a year-over-year increase of 128.34%.

Score

Industry at a Glance

Previous score

6.95

Change



Financials

5.90

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.43

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.86

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.58

Key Metrics

Free cash flow

No Data

X4 Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 7.05, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -0.24, which is -82932.85% below the recent high of 195.65 and -133769.31% above the recent low of -316.20.

Score

Industry at a Glance

Previous score

7.05

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 108/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 8.40, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for X4 Pharmaceuticals Inc is 7.50, with a high of 14.00 and a low of 3.50.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

8.400

Target Price

+111.59%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

X4 Pharmaceuticals Inc

XFOR

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 5.80, which is lower than the Pharmaceuticals industry's average of 6.99. Sideways: Currently, the stock price is trading between the resistance level at 4.46 and the support level at 2.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.06

Change

-0.26

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.092

Buy

RSI(14)

50.953

Neutral

STOCH(KDJ)(9,3,3)

42.987

Sell

ATR(14)

0.312

High Vlolatility

CCI(14)

13.059

Neutral

Williams %R

60.000

Sell

TRIX(12,20)

0.767

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

3.928

Sell

MA10

3.782

Sell

MA20

3.428

Buy

MA50

3.427

Buy

MA100

2.778

Buy

MA200

5.610

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 36.32%, representing a quarter-over-quarter decrease of 38.53%. The largest institutional shareholder is The Vanguard, holding a total of 231.89K shares, representing 0.38% of shares outstanding, with 92.07% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

New Enterprise Associates (NEA)

2.23M

+347.14%

BVF Partners L.P.

2.23M

Trails Edge Capital Partners LP

1.57M

Deep Track Capital LP

1.12M

Bain Capital Life Sciences Investors, LLC

495.99K

Craig (Adam R)

289.88K

Volpone (John)

289.88K

Kingdon Capital Management, L.L.C.

233.33K

-0.00%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 1.29, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.42. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.